Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD
- Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US
- Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.

Scope

- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Companies Mentioned
AbbVie
Aclaris
Akaal Pharma
Allergan
Amgen
Amorepacific Corporation
AnaptysBio
AntibioTx
AOBiome
Asana BioSciences
AstraZeneca
BioMimetix
Brickell Biotech
Celgene
Chugai
Connect Biopharma
Creabilis
Cutanea Life Sciences
Dermata Therapeutics
Dermavant Sciences
Dermira
DS Biopharma
Eli Lilly
Fountain Biopharma
Galapagos
Galderma
Galectin Therapeutics
Glenmark Pharma
GSK
Haus Bioceuticals
iCo Therapeutics
Immune Pharma
Incyte Corporation
Janssen
Japan Tobacco
Kang Stem Biotech
Kyowa Hakko Kirin
Leo Pharma
Medimetriks
MedImmune
Menlo Therapeutics
MorphoSys
NeRRe Therapeutics
Novan
Novartis
Otsuka
Pfizer
PurGenesis Technologies
Qurient
Ralexar Therapeutics
Realm Therapeutics
Regeneron
Roche
Roivant Sciences
Saniona
Sanofi
Shaperon
Sienna Biopharma
Sterna Biologicals
Therapeutics
Tioga
Valeant
Vanda Pharma
XBiotech
Xencor
Ziarco Pharma